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Abstract
Increasing evidence suggests that FOXO1 possesses a tumor suppressor function. Inactivation of FOXO1 has
been documented in many types of human cancer, and restoring the activity of FOXO1 holds promise for cancer
treatment. In this study, we identified a FOXO1-derived peptide termed FO1-6nls that inhibits cyclin-dependent
kinases 1 and 2 (CDK1/2)–mediated phosphorylation of FOXO1 at the serine 249 residue in vitro and in vivo. Over-
expression of FO1-6nls in prostate cancer (PCa) cells not only blocked CDK1-induced cytoplasmic localization of
FOXO1 but also augmented FOXO1’s transcriptional activity. This effect of FO1-6nls requires its binding to CDK1
and CDK2. Moreover, the ectopic expression of FO1-6nls inhibited the growth of PTEN-positive DU145 PCa cells.
Importantly, the growth-inhibitory function of FO1-6nls is dependent on FOXO1. Finally, the ectopic expression of
FO1-6nls overcame CDK1-mediated inhibition of FOXO1-induced apoptosis of PCa cells. These results indicate
that the FOXO1-derived peptide FO1-6nls can restore FOXO1’s tumor suppressor function by specifically opposing
CDK1/2–mediated phosphorylation and inhibition of FOXO1 and hence may have a therapeutic potential for the
treatment of PCa.
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Introduction
FOXO transcription factors in humans, including FOXO1 (FKHR),
FOXO3a (FKHRL1), FOXO4 (AFX), and FOXO6, play important
roles in regulating many cancer-related functions, such as apoptosis,
cell cycle arrest, DNA damage repair, and/or oxidative stress resistance,
depending on the cellular context [1]. Activation of FOXOs induces
transcription of the proapoptotic gene, FasL, by binding to the three
consensus FOXO binding sites in the FasL promoter [2]. Indeed,
forced expression of a constitutively active form of FOXO protein
induces apoptosis in cerebellar granule neurons through a mechanism
depending, at least in part, on FasL up-regulation [2]. Through an un-
biased gene profiling study, tumor necrosis factor–related apoptosis
inducing ligand (TRAIL), another death receptor ligand, was identified
as a FOXO1-regulated gene in prostate cancer (PCa) cells [3]. In addi-
tion to the death receptor ligands, FOXO proteins have been shown to
be involved in transactivation of the proapoptotic gene Bim [4–6]. In
addition, members of the FOXO family regulate G1 cell cycle progres-
sion by upregulating the cyclin-dependent kinase inhibitor p27KIP1 and
downregulating cyclin D1 and D2 [7–10]. FOXO transcription factors
also play a role in the surveillance of DNA damage by transcriptionally
regulating expression of the DNA damage response gene Gadd45 and
scavenger genes, such as cytosolic catalase and superoxide dismutase [11–
14]. These findings suggest that members of the FOXO family func-
tion as tumor suppressors. Support for this hypothesis also comes from
data demonstrating that activation of FOXO1 induces apoptosis in
PCa cells [3,8,15–17]. This observation further suggests that FOXO1
might be a potential target for PCa therapy.
The importance of FOXO proteins in human cancers is further re-
vealed by the fact that their functions are often disrupted by oncogenic
signaling pathways. The PTEN (also known asMMAC1/TEP1) tumor
Abbreviations: CDK, cyclin-dependent kinase; PCa, prostate cancer; nls, nuclear locali-
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suppressor gene is frequently mutated in a variety of human cancers
including PCa [18–20]. Biochemical and genetic studies demonstrate
that PTEN acts as a tumor suppressor protein by primarily antagoniz-
ing the phosphoinositide 3-kinase (PI3K)/Akt pathway [21]. Activation
of Akt due to loss of PTEN or treatment of cells with growth factors
leads to phosphorylation and inhibition of FOXO proteins [2,22–24].
In addition, a recent study demonstrated that hemizygous and homo-
zygous deletions in the FOXO1 gene locus are present in approximately
30% of PCa cell lines, xenografts, and a cohort of PCa specimens exam-
ined [25]. Thus, the function of FOXO1 is frequently abolished through
various mechanisms in human PCas, suggesting that FOXO1 is a
PCa-relevant tumor suppressor protein.
The tumor suppressor function of FOXO1 can also be inhibited
by other protein kinase pathways [1]. CDK1 and CDK2, two cell
cycle regulatory protein kinases that are important for cell cycle tran-
sitions from G1 to S and G2 to M, respectively, interact directly with
and phosphorylate FOXO1 at the serine 249 (S249) residue in PCa
cells [26,27]. This phosphorylation of FOXO1 attenuates the tumor
suppressor function of FOXO1 and thereby favors PCa cell growth and
survival. In this study, we identified a FOXO1-derived 70-amino acid
peptide that antagonizes CDK1- and CDK2-mediated phosphorylation
and inhibition of FOXO1. We further demonstrated that expression
of this peptide not only restores the tumor suppressor function of
FOXO1 but also inhibits growth and survival of PCa cells.
Materials and Methods
Plasmids, Small Interference RNA, and Chemicals
Plasmids for FLAG-tagged wild type (FOXO1-WT) and Akt
phosphorylation-resistant mutant (FOXO1-A3) of FOXO1 and the
luciferase reporter construct, 3×IRS, which contains three copies of the
FOXO response element in the promoter of the IGFBP1 gene, were
described previously [26]. The V5-tagged FO1-6nls (amino acids 211-
280) that encompasses the intact nuclear localization signal (nls) was
amplified by polymerase chain reaction using gene-specific primers
(forward 5′-CACCATGAATTCAATTCGTCATAATCTGTCC-3′,
reverse 5′-GCCAGACTGGAGAGATGCTTT-3′) and cloned in the
pcDNA3.1D/V5-His vector (Invitrogen, Carlsbad, CA). Plasmids for
active mutants of CDK1 (CDK1-AF) and CDK2 (CDK2-AF) and
amino acid substitution mutant of FOXO1-S249A/S298A were de-
scribed previously [26,27]. Various glutathione S -transferase (GST)–
FOXO1 fusion constructs were generated with the backbone vector
pGEX-4T-1 (GE Healthcare, Piscataway, NJ) as described [26]. The
SMARTpools of small interference RNAs (siRNAs) for human FOXO1
(5′-CCAGGCAUCUCAUAACAAA-3′; 5′-CCAGAUGCCUAUA-
CAAACA-3′) and FOXO3a (5′-CGAAUCAGCUGACGACAGU-3′;
5′-GUACUCAACUAGUGCAAAC-3′) and nonspecific siRNA (5′-
UAGCGACUAAACACAUCAA-3′) were purchased from Dharmacon
(Lafayette, CO). The PI3K inhibitor LY294002 was purchased from
Invitrogen. The working concentration of LY294002 was 20 μM.
Cell Culture, Transfection, and Luciferase Reporter Assay
The PCa cell lines LNCaP, DU145, and PC-3 were purchased from
the American Type Culture Collection (Manassas, VA). The immortalized
prostatic epithelial cell line BPH-1 was kindly provided by Dr S. W.
Hayward (Vanderbilt University Medical Center). Cells were cultured
in RPMI-1640 medium containing 10% fetal bovine serum (Hyclone,
South Logan, UT), 100 U/ml penicillin, and 100 μg/ml streptomycin.
Cells were maintained at 37°C and 5% of CO2. Transfections were
performed by electroporation using a Gene Pulse Electroporator (BTX,
Holliston, MA). Approximately 50% to 90% transfection efficiencies
were routinely achieved. For luciferase reporter assays, cells were harvested
at 36 to 48 hours after transfection, and cell lysates were subjected to the
measurement of activities of firefly and Renilla luciferases using a dual-
luciferase kit (Promega, Madison,WI). Renilla luciferase activities in cells
were used as an internal control. Both firefly and Renilla luciferase activ-
ities were measured using the Lumat LB 9507 luminometer (Berthold
Technologies, Oak Ridge, TN).
Immunoprecipitation and Western Blot
Protein immunoprecipitations were carried out using an immuno-
precipitation kit (Roche Applied Science, Indianapolis, IN). Western
blot was performed as described [28]. Briefly, protein samples were pre-
pared by lysing cells in modified radioimmune precipitation assay buffer
(1× phosphate-buffered saline [PBS], 1% Nonidet P-40, 0.1% sodium
dodecyl sulfate (SDS), and protease inhibitor cocktail [Sigma-Aldrich,
St Louis, MO]). Equal amounts of protein (50-100 μg) from cell lysates
were denatured in the sample buffer, subjected to SDS-PAGE gels, and
transferred to nitrocellulose membranes (Bio-Rad, Hercules, CA). The
filters were immunoblotted with specific primary antibodies, horseradish
peroxidase–conjugated secondary antibodies, and visualized by enhanced
chemiluminescence (GE Healthcare). A polyclonal antibody against
phosphorylated S249 of FOXO1 (S249-p) was raised by immunizing
rabbits with the phosphorylated peptide NPEGGKSGKpSPRRRAAS
and purified over a peptide-affinity column as described [26]. Other
protein-specific antibodies were as follows: anti-FOXO1, anti-CDK1,
anti–cyclin B1, and anti–poly(ADP-ribose) polymerase (PARP; Cell
Signaling Technology, Danvers, MA); anti-Erk2 mAb (Santa Cruz
Biotechnology, Santa Cruz, CA); anti-V5 (Invitrogen); anti-FLAG (M2)
(Sigma-Aldrich); anti-FOXO3a (Millipore, Billerica, MA); and anti-Bim
(Chemicon, Billerica, MA).
Immunofluorescent Chemistry and Confocal Microscopy
Cells grown on coverslips (Eppendorf Scientific, Inc, Hauppauge,
NY) were washed briefly in 1× PBS and fixed for 20 minutes in 2%
paraformaldehyde (Thermo Fisher, Pittsburgh, PA) in 1× PBS. Cells
were permeabilized by incubating with 0.2%Triton X-100 for 15 min-
utes. Cells were washed three times in 1× PBS and incubated in block-
ing buffer (5% goat serum in 1× PBS) for 1 hour at room temperature.
Cells were incubated with a mouse anti-FLAG monoclonal antibody
(1:1000) for 2 hours at room temperature. After washing with 1× PBS
three times for 5 minutes each, cells were incubated for 1 hour at room
temperature with the secondary Alexa Fluor 488–labeled goat antimouse
IgG conjugate (Invitrogen) (1:5000) prepared in blocking buffer for
1 hour at room temperature. Coverslips were washed with three changes
of 1×PBS for 5minutes each andmounted in VECTASHIELDMount-
ing Medium with 4′,6-diamidino-2-phenylindole (Vector Laboratories,
Burlingame, CA). Cells were analyzed with a laser-scanning microscope
(FluoView 1000; Olympus, Center Valley, PA). An argon ion laser
was used to excite Alexa Fluor 488, and a UV laser was used to excite
4′,6-diamidino-2-phenylindole.
Apoptosis and Cell Viability Assay
Apoptosis analysis was performed as described [27]. Briefly, cells were
stained with a solution containing 0.1% Triton X-100, 20 μg/ml of
propidium iodide, and 50 μg/ml of RNase A. Hypodiploid cells were
determined by flow cytometry using a FACScan (Becton-Dickinson,
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Franklin Lakes, NJ). The percentage of sub-G1 cells was analyzed by BD
CellQuest Pro software. Cell viability was assessed by means of trypan blue
exclusion using Vi-Cell cell viability analyzer (Beckman Coulter, Brea, CA).
GST Fusion Protein Purification and GST Pull-down Assay
The plasmids expressing GST fusion genes were constructed and
transformed into Escherichia coli BL21 star strains as described previ-
ously [26]. For protein purification, bacteria were grown to an optical
density of 0.6 at 600 nm in Luria-Bertani medium, induced at 37°C
with 0.1 mM of isopropyl-1-thio-D-galactopyranoside, and cultivated
for 3 hours. Bacteria were then pelleted, resuspended in lysis/pull-down
buffer (100 mM NaCl, 1 mM EDTA, 50 mM Tris-HCl, pH 7.4,
0.5% Nonidet P-40, 1 mM phenylmethyl-sulfonyl-fluoride, 5 mM
benzamidine, and bacterial protein inhibitors), and sonicated. Insoluble
materials were removed by centrifugation. Glutathione S-Sepharose 4B
beads (GE Healthcare) were added to the cleared lysate, incubated over-
night at 4°C, and washed three times with the pull-down buffer. GST
fusion proteins on beads were estimated by comparison to GST protein
standard after SDS-PAGE and Coomassie blue staining. In vitro tran-
scription and translation of CDK1 protein was performed according to
the manufacturer’s instruction (TnT Quick Coupled Transcription/
Translation Systems; Promega). GST pull-down assays were carried
out as described previously [26].
In Vitro Kinase Assay
Kinase assays were carried out in the presence of [γ-32P] ATP by using
an in vitro kinase buffer system obtained from Cell Signaling Technol-
ogy as described [26]. The reconstituted CDK1/cyclin B1 and CDK2/
cyclin E complexes obtained from Cell Signaling Technology were
incubated with various substrates at 30°C. Thirty minutes after reac-
tion, proteins were subjected to SDS-PAGE and autoradiography.
Results
Identification of a Peptide of FOXO1 That Inhibits CDK1/2
Phosphorylation of FOXO1 In Vitro
Previous studies show that CDK1 and CDK2 phosphorylate FOXO1
at S249 and that S249 phosphorylation diminishes FOXO1-mediated
gene transactivation and inhibition of PCa cell growth and survival
[26,27]. In the present study, we aimed to determine whether FOXO1-
derived small peptides could function as a decoy that interferes with
CDK1- and CDK2-mediated phosphorylation of FOXO1 at S249.
Similar to the previous reports [26,27], two S249-containing fragments
of FOXO1, FO1-3 (amino acids 211-419) and FO1-2 (amino acids
149-267) (Figure 1A), were phosphorylated by CDK2/cyclin E in vitro
(Figure 1B). Importantly, CDK2-mediated phosphorylation of FO1-3
and FO1-2 was inhibited, in a dose-dependent manner, by the small
peptide FO1-6 (amino acids 211-267), an S249-containing fragment
of FOXO1 that is overlapped by FO1-3 and FO1-2 (Figure 1, A and
B). As a control, addition of the same concentrations of GST proteins
has no inhibitory effect on CDK2-mediated phosphorylation of FO1-2
and FO1-3 (data not shown). The COOH-terminus of the retino-
blastoma (RB) protein (RB-C) is a well-known substrate of CDK2.How-
ever, CDK2-mediated phosphorylation of RB-C was not affected by
FO1-6 (Figure 1C ). These data suggest that the effect of FO1-6nls
is FOXO1-specific. Similarly, CDK1-mediated phosphorylation of
FO1-2 and FO1-3 was also inhibited by FO1-6 (data not shown). These
results indicate that the FOXO1-derived small peptide FO1-6 can specifi-
cally inhibit CDK1/2–mediated phosphorylation of FOXO1 in vitro.
FO1-6nls Inhibits FOXO1 Phosphorylation at S249 in PCa Cells
It has been shown recently that forced expression of CDK1 or CDK2
inhibits the transcriptional activity of the nuclear form of FOXO1,
FOXO1-A3, in which three Akt phosphorylation residues are converted
to alanine [26,27]. This finding suggests that CDK1/2 target FOXO1
in the nucleus. To examine the effect of the small peptide FO1-6 on
S249 phosphorylation of FOXO1 in cells, we engineered a V5-tagged
nucleus-targeting expression vector for this peptide by including 13 ad-
ditional amino acids beyond the COOH-terminus of FO1-6, which
constitute an essential portion of the functional nuclear localization sig-
nal (nls) in FOXO1 (Figure 1A) [29]. It was thus termed V5-FO1-6nls
to reflect the nature of this construct that contains the intact nls. To
determine the effect of FO1-6nls expression on S249 phosphorylation
of endogenous FOXO1, the DU145 PCa cell line was used because
it expresses high levels of endogenous FOXO1 [3]. As shown in Fig-
ure 2A, S249 phosphorylation of endogenous FOXO1 was completely
abolished by the expression of FO1-6nls in these cells. In agreement
with the previous reports [26,27], the ectopic expression of constitutively
active CDK1 and CDK2 increased S249 phosphorylation of ectopically
expressed FOXO1 in LNCaP PCa cells (Figure 2, B and C , lane 2 vs 1),
in which expression of endogenous FOXO1 is relatively low [3]. Im-
portantly, CDK1/2–induced increase in FOXO1 phosphorylation at
S249 was inhibited by FO1-6nls in a dose-dependent manner (Figure 2,
B and C , lane 3, 4 vs 2). These results are consistent with the finding
from the in vitro kinase assay that in vitro phosphorylation of FO1-3
mediated by the constituted CDK2/cyclin E complex was inhibited by
FO1-6nls (Figure 1D). These data indicate that FO1-6nls expression
overcomes CDK1- and CDK2-mediated phosphorylation of FOXO1
at S249 in PCa cells.
FO1-6nls Overcomes CDK-Mediated Inhibition of FOXO1’s
Transcriptional Activity and Nuclear Exclusion of FOXO1
It has been reported previously that CDK1- and CDK2-mediated
phosphorylation of FOXO1 at S249 inhibits FOXO1’s transcriptional
activity [26,27]. Next, we sought to determine whether expression of
FO1-6nls affects CDK1/2 inhibition of FOXO1 activity. As expected,
forced expression of constitutively active CDK2 (CDK2-AF) and cyclin
E inhibited the transcriptional activity of FOXO1 in LNCaP cells as
demonstrated by luciferase reporter gene assays (Figure 3A). However,
this effect of CDK2/cyclin E was completely reversed by the expres-
sion of FO1-6nls (Figure 3A). It is worth noting that transfection of
FO1-6nls alone resulted in a limited increase in the transcriptional
activity of endogenous FOXO1 (Figure 3A, lane 5 vs 1). This is pre-
sumably because of the low level of endogenous FOXO1 protein [30]
and the inhibition of FOXO1 caused by Akt-mediated phosphoryla-
tion in this PTEN-mutated PCa cell line [18]. A similar result was
observed in PC-3 cells (Figure 3B, left), another PCa cell line that ex-
presses a low level of endogenous FOXO1 [3] and lacks PTEN [18].
In line with this notion, pretreatment of PC-3 cells with the PI3K in-
hibitor LY294002 increased the transcriptional activity of FOXO1 pro-
teins, and this effect was further enhanced in cells transfected with
FO1-6nls (Figure 3B, left). Similar to a previous report [8], wild-type
FOXO1 proteins were primarily localized in the cytoplasm of PTEN-
null PC-3 cells cultured in media containing growth factors (Figure 3B,
right, column 1). In agreement of the gene reporter results (Figure 3B,
left), transfection of FO1-6nls had a minimal effect on nuclear localiza-
tion of FOXO1 under these conditions (Figure 3B, right, column 2). As
expected, most FOXO1 proteins were localized in the nucleus of PC-3
after LY294002 treatment (Figure 3B, right, column 3). Importantly,
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FOXO1 proteins were primarily localized in the nucleus of PC-3 cells
treated with FO1-6nls and LY294002 (Figure 3B, right, column 4 ).
Thus, similar to the results obtained from the gene reporter assays
(Figure 3B, left), the effect of FO1-6nls on the cellular localization of
FOXO1 proteins is markedly affected by the activation of PI3K/Akt.
Consistent with these observations, the ectopic expression of FO1-6nls
alone was sufficient to enhance the transcriptional activity of endogenous
FOXO proteins in a dose-dependent manner in PTEN-positive DU145
cells (Figure 3C). These data indicate that the expression of FO1-6nls
increases FOXO1 transcriptional activity, and this effect can be atten-
uated by loss of PTEN and/or activation of Akt.
Next, we sought to determine whether FO1-6nls–induced activation
of FOXO1 is mediated by its inhibition of CDK phosphorylation of
FOXO1. To this end, BPH-1 cells were used because, in this cell line,
CDKs are highly active owing to the inactivation of RB and p53 medi-
ated by SV40 large T antigen [31]. Cotransfection of FO1-6nls with
FOXO1 increased the transcriptional activity of wild-type FOXO1 in
BPH-1 cells (Figure 3D). The expression of FO1-6nls failed to increase
the transcription activity of a mutant of FOXO1 that is resistant to
CDK-mediated phosphorylation and inhibition of FOXO1 [26,27].
As expected, this mutant exhibited a higher basal transcriptional activ-
ity than the wild-type FOXO1 (Figure 3D). These results suggest that
Figure 1. FOXO1-derived peptides FO1-6 and FO1-6nls inhibit CDK2-mediated phosphorylation of FOXO1 in vitro. (A) A schematic diagram
showing GST-FOXO1 recombinant proteins and the amino acid sequence of the small peptide FO1-6nls that contains the S249 phosphory-
lation site. FKH indicates forkhead domain; NLS/nls, nuclear localization signal; NES, nuclear export signal; TA, transactivation domain.
(B) Reconstituted CDK2/cyclin E kinase assays using FO1-3 plus FO1-6 (left panels) or FO1-2 plus FO1-6 (right panels) as substrates.M r(KD),
relative molecular weight in kilodaltons. (C) Reconstituted CDK2/cyclin E kinase assays using the RB-C protein and FO1-6 as substrates.
(D) Reconstituted CDK2/cyclin E kinase assays with substrates of FO1-3 and FO1-6nls. All the experiments were repeated at least two times.
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FO1-6nls acts as a “decoy”molecule that activates FOXO1’s transcriptional
activity by antagonizing CDK1/2–mediated phosphorylation of FOXO1.
Because CDK2 inhibits FOXO1 by promoting FOXO1 phosphory-
lation and nuclear exclusion in PTEN-positive DU145 PCa cells [26],
we sought to determine whether the expression of CDK1 also affects
cellular localization of the FOXO1 protein and whether this process
could be blocked by the expression of FO1-6nls. In accordance with
the previous report [26], ectopically expressed wild-type FOXO1 pro-
teins were mainly localized in the nucleus of DU145 cells when they
were cultured in growth factor–depleted conditions (Figure 3E). Simi-
lar to the effect of CDK2 [26], overexpression of constitutively active
CDK1 (CDK1-AF) and cyclin B1 resulted in the nuclear exclusion
of FOXO1 in DU145 cells (Figure 3E). Importantly, cotransfection
of FO1-6nls blocked CDK1-induced nuclear exclusion of wild-type
FOXO1 (Figure 3E). Thus, FO1-6nls prohibits nuclear exportation
of FOXO1 induced by CDK1 in DU145 PCa cells. This result is
consistent with the FO1-6nls–enhanced transcriptional activity of
FOXO1 in this cell line.
FO1-6nls Binds to CDK1 and CDK2 Proteins
To further explore the molecular mechanism underlying the antago-
nistic effect of FO1-6nls on CDK1/2–mediated phosphorylation of
FOXO1, we sought to determine whether FO1-6nls binds to CDK1
and CDK2. Toward this end, bacterially expressed GST recombinant
FO1-6nls and FO1-3 fusion proteins (Figure 4A) were purified, and
GST pull-down assays were performed by incubating the fusion pro-
teins with whole-cell lysate of BPH-1 prostatic cells. Consistent with
previous reports [26,27], FO1-3 bound to CDK2 (Figure 4B). FO1-
6nls also bound to CDK2 in a manner similar to FO1-3 (Figure 4B). No
binding of CDK2 to GST proteins was detected in these experiments
(Figure 4B), suggesting that the binding of FO1-6nls to CDK2 is spe-
cific. In vitro protein binding assays demonstrated that FO1-6nls binds
to the CDK1 protein produced from in vitro transcription and transla-
tion (Figure 4C ), suggesting that FO1-6nls binds directly to CDK1.
Different from FO1-6nls, however, three NH2-terminal truncated mu-
tants of FO1-6nls, including FO1-6nls-Δ211-223, FO1-6nls-Δ211-233
and FO1-6nls-Δ211-243, failed to bind to CDK1 (Figure 4C ). This
result suggests that the 13 amino acids (211-223) in the NH2-terminus
of FO1-6nls are important for the binding of FO1-6nls to CDK1.
Thirteen Amino Acids in the NH2-Terminus of FO1-6nls
Are Important for the Antagonistic Effect of FO1-6nls on
CDK-Mediated Inhibition of FOXO1
Next, we sought to determine whether the 13-amino acid motif is
important for FO1-6nls–mediated activation of FOXO1. Unlike FO1-
6nls, expression of all three truncation mutants of FO1-6nls, including
FO1-6nls-Δ211-223, FO1-6nls-Δ211-233, and FO1-6nls-Δ211-243,
failed to increase FOXO1 transcriptional activity in DU145 cells (Fig-
ure 4D). Because all these truncation mutants contain the CDK phos-
phorylation receptor site S249 (Figure 4A), these results suggest that
the presence of the CDK phosphorylation residue in FO1-6nls may
not be important for its decoy function. Indeed, this notion was fur-
ther supported by the result that the expression of FO1-6nls-S249A, a
substitution mutant of FO1-6nls in which the S249 residue was con-
verted into alanine, increased the transcriptional activity of FOXO1 as
effectively as the unmutated FO1-6nls did (Figure 4D, column 7 vs 3).
These observations suggest that the binding of FO1-6nls to CDK1 and
CDK2, but not the phosphorylation acceptor residue S249 in FO1-
6nls, is important for its antagonistic effect on CDK1- and CDK2-
mediated inhibition of FOXO1.
FO1-6nls–Mediated Inhibition of PCa Cell Growth Is
Dependent on FOXO1
As shown in Figure 3C , the expression of FO1-6nls alone en-
hanced transcriptional activity of endogenous FOXO proteins in
Figure 2. FO1-6nls inhibits phosphorylation of FOXO1 at S249 in
PCa cells. (A) DU145 cells grown in the exponential phase were
harvested and lysed for immunoprecipitation with anti-FOXO1 anti-
bodies and Western blot analysis with antibodies as indicated.
Immunoblot analysis of Erk2 was used as a loading control. (B, C)
LNCaP cells were transfected with FLAG-tagged FOXO1 plus cyclin
B1 and CDK1-AF (B) or cyclin E and CDK2-AF (C). At 48 hours after
transfection, cells were lysed and subjected to immunoprecipitation
with anti-FLAG (M2) antibodies. Immunoprecipitates were analyzed
by Western blot using antibodies as indicated. Similar results were
obtained from at least two independent experiments.
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PTEN-positive DU145 cells. This observation prompted us to evaluate
the antitumor effect of FO1-6nls in this cell line without exogenous
expression of FOXO1. As demonstrated in Figure 5A, expression of
FO1-6nls inhibited growth of DU145 cells in a dose-dependent man-
ner. To test the possibility that expression of FO1-6nls may affect the
growth of PCa cells by acting on other FOXO proteins, we individually
knocked down FOXO1 and FOXO3a, two members of the FOXO
family that are predominantly expressed in PCa cell lines [3,26]. As
expected, treatment of cells with a nonspecific control siRNA had
little or no effect on FO1-6nls–mediated inhibition of cell growth (Fig-
ure 5B). Silencing of FOXO1, but not FOXO3a by a pool of gene-
specific siRNAs, completely abolished FO1-6nls–mediated inhibition
of DU145 cell growth, suggesting that the inhibitory effect of FO1-
6nls on the growth of DU145 PCa cells is mediated by FOXO1. This
observation is consistent with the previous finding that the consensus
CDK phosphorylation residue is present in FOXO1 (S249) but not in
FOXO3a and FOXO4 proteins and that forced expression of CDK2/
cyclin E inhibits FOXO1’s but not other FOXO protein’s transcrip-
tional activity [26].
Expression of FO1-6nls Antagonizes CDK1-Mediated
Inhibition of FOXO1-Induced Apoptosis of PCa Cells
Previous studies demonstrated that the ectopic expression of
FOXO1-A3, a constitutively active mutant of FOXO1, induces apop-
tosis in PTEN-mutated LNCaP PCa cells [8,17]. Moreover, the
ectopic expression of CDK1 inhibits FOXO1-A3–induced apoptosis,
and this effect is mediated by CDK1 phosphorylation of FOXO1 at
S249 [27]. We examined whether FO1-6nls expression affects CDK-
mediated inhibition of FOXO1-induced apoptosis of PCa cells. As
expected, the expression of FOXO1-A3 in LNCaP cells resulted in an
Figure 3. FO1-6nls augments FOXO1’s transcriptional activity and antagonizes CDK1-induced nuclear exclusion of FOXO1. (A) The antago-
nistic effect of FO1-6nls on CDK2-mediated inhibition of FOXO1’s transcriptional activity. LNCaP cells were transfected with plasmids as
indicated. At 36 hours after transfection, luciferase activities were measured and analyzed as described in the Materials and Methods
section. Error bars, SD of three independent experiments. (B) Effect of FO1-6nls on the transcriptional activity (left) and cellular localiza-
tion (right) of FOXO proteins in PTEN-null PC-3 cells. Left, PC-3 cells were transfected with FO1-6nls and/or pretreated with the PI3K in-
hibitor LY294002, and luciferase activities were measured as described in A. Right, PC-3 cells were transfected with plasmids as indicated
and plated in serum-containing media. At 24 hours after transfection, cells were treated with LY294002 (20 μM) or vehicle for 12 hours.
Cells were then subjected to immunofluorescent chemistry with antibodies indicated. (C) Effect of FO1-6nls on the transcriptional activity
of endogenous FOXO1 proteins in PTEN-positive DU145 cells. Cells were transfected with the reporter gene 3×IRS-Luc and different
amount of FO1-6nls. At 36 hours after transfection, luciferase activities were measured and analyzed as described in A. Error bars, SD
of three independent experiments. (D) BPH-1 cells were transfected with plasmids as indicated and subjected to luciferase activity mea-
surement as in A. (E) DU145 cells transfected with plasmids as indicated and plated in serum-free media. At 48 hours after transfection,
cells were subjected to immunofluorescent chemistry with antibodies indicated.
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increase in apoptosis in comparison to the expression of the empty vec-
tor (Figure 6A). This effect was completely inhibited by cotransfection
with the constitutively active CDK1 (CDK1-AF). However, CDK1-
mediated inhibition of FOXO1-induced apoptosis was reversed by
FO1-6nls in a dose-dependent manner (Figure 6A). Transfection of
FO1-6nls alone resulted in a slight increase in apoptosis relative to
the transfection of the empty vector (Figure 6A), which is consistent
with the very limited increase in the transcriptional activity of endoge-
nous FOXO1 in this PTEN-mutated cell line when transfected with
FO1-6nls alone (Figure 3A, column 5 vs lane 1). Background apoptosis
was observed when cells were transfected with the empty vector. This
is presumably because of the cell debris generated by the transfection
method of electroporation and the weak-adhesive nature of LNCaP
cells as reported previously [27]. The quantitative results of these ex-
periments are shown in Figure 6B (upper panel). In line with these
results, the ectopic expression of FOXO1-A3 induced expression of
Bim (Figure 6B), a proapoptosis gene transcriptionally activated by
FOXO1 [6]. This effect was inhibited by the expression of CDK1-
AF (Figure 6B). However, CDK1-mediated inhibition of Bim expres-
sion was abolished in FO1-6nls–transfected cells (Figure 6B). A similar
result was observed for the cleavage of PARP, an apoptotic marker
(Figure 6B). These data suggest that FO1-6nls can antagonize CDK-
mediated inhibition of FOXO1, thereby restoring the apoptotic func-
tion of FOXO1 in PCa cells.
Discussion
Findings from human and mouse studies suggest that FOXO tran-
scription factors function as tumor suppressors by promoting cell
cycle arrest and apoptosis [26,32]. The relevance of these proteins to
human cancers is further evident in the fact that their tumor suppres-
sor functions are often disrupted by many oncogenic pathways [1].
Thus, specifically restoring the tumor suppressor function of FOXO1
in cancerous cells would be of great interest for the treatment of
human cancers. In the present study we demonstrated that FO1-
6nls, a 70-amino acid peptide of FOXO1 that contains the CDK phos-
phorylation site S249, binds directly to CDK1 and CDK2 and blocks
CDK1/2–mediated phosphorylation of FOXO1 both in vitro and
in vivo. Consistent with the previous findings that S249 phosphorylation
is important for CDK1/2–induced nuclear exclusion and inhibition of
FOXO1 [26,27], the expression of FO1-6nls impedes CDK-induced
nuclear exclusion of FOXO1, augments FOXO1’s transcriptional
activity and inhibits PCa cell growth and survival. Therefore, we have
Figure 4. The 13 amino acids in the NH2-terminus of FO1-6nls are important for the binding of FO1-6nls to CDK1 and FO1-6nls–induced
activation of FOXO1. (A) Schematic diagram depicting GST-FOXO1 recombinant peptides. (B) GST pull-down assay with GST-FOXO1 fusion
proteins FO1-3 and FO1-6nls using BPH-1 prostatic cell lysate. (C) Binding assays with CDK1 proteins produced by in vitro transcription
and translation and GST-FOXO1 recombinant peptides shown in A. Top, Autoradiography of 35S-labeled CDK1 protein bound to GST-
FOXO1 recombinant peptides. Middle, Input of 35S-labeled CDK1 protein used in the in vitro protein binding assays. Bottom, GST and
GST-FOXO1 recombinant peptides for in vitro protein binding assays indicated by Coomassie blue staining. (D) DU145 cells were trans-
fected with plasmids as indicated. At 36 hours after transfection, cells were harvested and lysed for luciferase activity measurement.
Error bars, SD of three independent experiments.
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identified a novel, biologically active polypeptide of FOXO1 that
enables to restore FOXO1’s transcriptional and antitumor activities by
specifically overcoming CDK1- and CDK2-mediated phosphorylation
and inhibition of FOXO1.
The finding that the decoy function of FO1-6nls was not affected by
the S249A mutation in this peptide suggests that the antagonistic effect
of FO1-6nls on CDK phosphorylation of FOXO1 is independent of
the phosphorylation acceptor site S249. Mechanistically, we further
showed that FO1-6nls binds directly to CDK1 and CDK2 and that
deletion of 13 amino acids at the N-terminus of FO1-6nls abolishes
the interaction between FO1-6nls and CDK1 and CDK2. This dele-
tion also completely abrogates the ability of FO1-6nls in activation of
FOXO1. On the basis of these observations, we envision a working
model wherein the competitive binding of FO1-6nls to CDK1 and
CDK2 disrupts the binding of FOXO1 by CDK1 and CDK2, thereby
abolishing CDK1- and CDK2-mediated phosphorylation and nuclear
exclusion of FOXO1 and inhibition of FOXO1’s transcriptional ac-
tivity. The finding that the biologic activity of FO1-6nls is mediated
by its specific disruption of FOXO1-CDK interaction provides a plau-
sible explanation for the observation that the effect of FO1-6nls on
cell growth is dependent on FOXO1, but not FOXO3a, although
FOXO3a is also dominantly expressed in PCa cells. Importantly, this
result is consistent with the previous finding that no functional CDK
phosphorylation sites were identified in other FOXO proteins includ-
ing FOXO3a and FOXO4 [26].
It is well established that cyclin-CDK complexes, such as cyclin
A–CDK2 and cyclin E–CDK2, target their inhibitors, activators,
and other cell cycle regulators (e.g. p21WAF1, E2F1, p107, and p130)
through the binding of the cyclin subunits to a cyclin-binding sequence
(also known as a Cy or RXL motif ) present in their substrates [33,34].
A number of primary sequence elements, which loosely resembles
the RXL motif, are also identified in a region (amino acids 792-928)
of RB protein. Conversion of one of these elements to three alanine
residues diminishes cyclin A–CDK2–mediated phosphorylation of
RB [33]. It is worth noting that there is no RXL motif present in
FO1-6nls (Figure 1A). Moreover, unlike RXL-containing substrates
such as p21WAF1 and RB, which bind directly to the cyclin subunit,
rather than the CDK catalytic subunit of the CDK complex, FOXO1
directly binds to CDK1 and CDK2 [26,27]. Thus, CDK may inhibit
the function of FOXO1 and RB through distinctive mechanisms.
Deregulation of the cell cycle is one of the hallmarks of cancer
cells. Most importantly, expression and/or activity of CDK1 and
CDK2 often increase in human PCas. The expression of p27KIP1, a
well-characterized inhibitor of CDK2, frequently decreases in advanced
PCa [35]. Decreased levels of this protein are correlated with poor
clinical outcome [35,36]. These clinical findings suggest that increased
activity of CDK2 owing to loss of p27KIP1 is important for PCa pro-
gression. Because p27KIP1 can also bind to and inhibit CDK1 [37,38],
loss of p27KIP1 may lead to increased activity of CDK1 in PCa. More-
over, several groups have shown increased expression of the CDK1
protein in human PCas relative to normal prostatic tissues [39–41].
Furthermore, Cdc25C, the upstream activator of CDK1, not only is
upregulated in PCa but also is present exclusively in its active form
[42]. Loss-of-function mutations of the Chk2 gene, an upstream nega-
tive regulator of CDK1 and CDK2, have been detected in PCa speci-
mens [43,44]. These observations in clinic specimens support the view
that aberrant activation of CDK1 and CDK2 may lead to the inhibi-
tion of the tumor suppressor function of FOXO1, thereby promoting
PCa survival and/or resistance to therapy. The prevalence of CDK1/2–
mediated FOXO1 inhibition in human PCas and the effectiveness of
FO1-6nls in reversing this process highlight a therapeutic potential of
FO1-6nls for the treatment of PCa.
In summary, we have identified a bioactive, FOXO1-derived peptide
FO1-6nls that blocks S249 phosphorylation of FOXO1 mediated by
CDK1 and CDK2. In addition, expression of FO1-6nls overcomes
CDK1-induced nuclear exclusion and inhibition of FOXO1. Con-
sistently, treatment of PTEN-positive PCa cells with FO1-6nls alone
induces the expression of FOXO1 target genes, such as Bim, and pro-
motes apoptosis and inhibits cell growth. Thus, FO1-6nls may be
harnessed for the development of novel therapeutics for the treatment
of human cancers such as PCa.
Figure 5. FO1-6nls expression inhibits PCa cell growth in a FOXO1-
dependent manner. (A) DU145 cells were transfected with different
amounts of FO1-6nls plasmids. At 48 hours after transfection, cells
were harvested, and viable cells were counted as described in the
Materials and Methods section. (B) DU145 cells were transfected
with plasmids and control or gene-specific siRNAs as indicated. At
48 hours after transfection, cells were harvested and subjected to
cell viability measurement or Western blot analysis. Data are shown
as mean ± SD of three independent experiments.
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Figure 6. FO1-6nls expression overcomes CDK1-mediated inhibition of FOXO1-induced apoptosis in LNCaP PCa cells. (A) Representa-
tive images of flow cytometry. LNCaP cells were transfected with plasmids as indicated. At 48 hours after transfection, cells were har-
vested, fixed, and stained with propidium iodide (PI), and FACS analysis was performed. The percentage of cells at sub-G1 (apoptotic
cells) is indicated in each experiment. (B) Quantification results from three independent experiments. The expression of FOXO1, CDK1,
cyclin B1, and the proapoptotic protein Bim and the cleavage of PARP protein were examined by Western blots. These experiments were
repeated at least twice.
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